Novartis Vaccines and Diagnostics (Novartis) has received feedback from FDA in the form of an initial regulatory determination. Feedback was for the Biologics License Application (BLA) for the
Nutrition 21 announced that the European Food Safety Authority (EFSA) has released its safety assessment supporting the use of chromium picolinate in food supplements in the EU. In
Chelsea has reached its target enrollment of 82 patients for Study 302, the first of two pivotal phase-III clinical trials in Chelsea’s registration program of Droxidopa. It is
BioGaia has signed an agreement with Semper, which gives Semper exclusive rights to distribute a product combining BioGaia’s patented probiotic and ORS in one single packaging, in Sweden
CytRx has filed a report with FDA in response to the Agency’s partial hold on the clinical trial of its molecular chaperone regulator drug candidate, Arimoclomol. Arimoclomol is
Pfizer has discontinued SUN 1122 phase-III trial for the evaluation of Sutent (sunitinib malate) plus Folfiri versus Folfiri alone, for the first-line treatment of metastatic colorectal cancer. Data
Calixa has initiated a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections (UTI). CXA-101 is a parenteral cephalosporin antibiotic with in-vitro and in-vivo
Reitermann succeeds Dr. Heinrich Kolem, who will assume the role of global head of Siemens Healthcare’s Angiography, Fluoroscopy and X-ray business unit, based in Forchheim, Germany. Reitermann has
ImmunoCellular (IMUC) has reported the issuance of a Japanese patent relating to the company’s monoclonal antibody therapeutics. Patent No. 4287147 is titled Monoclonal Antibodies and Cell Surface Antigens
Bayer Schering Pharma (Bayer Schering) has signed a license agreement with Celera, which provides Bayer Schering with access to five cancer-related targets for therapeutic development and in-vivo diagnostic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.